Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

Invest2live Aug. 24 at 4:26 AM

$NVDA 1548% already; congrats 🪷🌟🌺 Checkout $TDC, $RXRX and $POET; excellent potential for longs. Do your DD and get in.

0 · Reply

Invest2live Aug. 24 at 4:20 AM

$UMC 138% already; congrats 🪷🌟🌺 Checkout $POET and $RXRX; both have similar or better potential. Do your DD and get in.

0 · Reply

Primitivetablemaker Aug. 23 at 5:12 PM

$RXRX In.

0 · Reply

USAEquityResearch Aug. 23 at 4:34 PM

$RXRX 📊 USAEquityResearch ▲ 3.50 (+4.79%) Trend: Bullish 📈 RSI (14): 60.8 — strong momentum, approaching overbought MACD: bullish, above signal line and rising Volume: above average 📌 Key Levels Resistance: 3.50 | Support: 2.97 20-MA: 3.20 | 50-MA: 3.28 💼 Fundamentals Mkt Cap: $1.88B FCF: $-219.49M (-0.41/sh) Total Debt: $66.64M D/E: 7.28 📉 Options (exp 2026-08-28) ATM IV: 81.3% | Skew: +0.0% (balanced) P/C Ratio: 0.26 🐂 Bullish lean Max Pain: 3.00 Call wall: 4.00 | Put wall: 3.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/RXRX

0 · Reply

LoveRetailFroth Aug. 22 at 2:41 PM

$AMLX Good Saturday Morning Folks☕️ I posted when I was down 15% last couple of weeks, so why not post when I am up😂 My portfolio grew an astonishing 30% last week finally achieving positive returns for the yr thanks to this 💎, $RXRX $SANA & $TEM $MRNA I see more crazy upside in all these next week. GL & have a great weekend!

0 · Reply

AEngelen Aug. 22 at 1:34 PM

$RXRX The trades were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025 — well before his CEO-to-Chairman transition was even announced (Nov 5, 2025) and before he decided to leave the board (mid-2026).

0 · Reply

LoveRetailFroth Aug. 22 at 1:55 AM

$AMLX What week folks! $MRNA $RXRX $SANA Have a great weekend 🍺

1 · Reply

LoveRetailFroth Aug. 21 at 10:24 PM

$MRNA Hoe are the bears feeling?😂🍺 $AMLX $RXRX $SANA

0 · Reply

LoveRetailFroth Aug. 21 at 6:31 PM

$RXRX $SANA Was busy with a small psychedelic $JUNS all morning 🍺

0 · Reply

CamRanhKid Aug. 21 at 6:00 PM

$RXRX 4 coming soon

0 · Reply

Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley

Aug 11, 2026, 10:00 AM EDT - 12 days ago

Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference

Aug 5, 2026, 8:00 AM EDT - 18 days ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 18 days ago

Recursion Pharmaceuticals Quarterly report: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 18 days ago

Recursion Pharmaceuticals Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 18 days ago

Recursion Pharmaceuticals Slides: Q2 2026

2026-08-05T10:45:39.000Z - 18 days ago

Recursion Pharmaceuticals reports Q2 EPS (25c), consensus (23c)

Aug 5, 2026, 6:30 AM EDT - 18 days ago

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Aug 4, 2026, 8:00 AM EDT - 19 days ago

Recursion to Participate in Upcoming Investor Conferences

Jul 31, 2026, 4:30 PM EDT - 23 days ago

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Jul 29, 2026, 8:30 AM EDT - 25 days ago

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

2026-06-25T00:25:13.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: AGM 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 19, 2026, 12:07 PM EDT - 3 months ago

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

2026-05-14T16:25:57.000Z - 3 months ago

Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley

May 12, 2026, 1:00 PM EDT - 3 months ago

Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:49 AM EDT - 3 months ago

These 10 ‘HALO' stocks protect your portfolio from the AI bubble

AWR ES HTO PCG PPL SR SRE

2026-05-07T09:29:09.000Z - 3 months ago

Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Slides: Q1 2026

May 6, 2026, 6:30 AM EDT - 3 months ago

Recursion Reports First Quarter Financial Results and Provides Business Update

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Recursion Announces Board Transition

2026-04-30T15:21:19.000Z - 4 months ago

Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 7:59 AM EDT - 4 months ago

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Apr 13, 2026, 12:45 PM EDT - 4 months ago

Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 9:00 AM EDT - 5 months ago

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

2026-03-25T12:06:43.000Z - 5 months ago

Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer

EXEL

Mar 25, 2026, 7:59 AM EDT - 5 months ago

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Mar 17, 2026, 3:45 PM EDT - 5 months ago

Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:50 AM EST - 6 months ago

Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 6:30 AM EST - 6 months ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 6 months ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Feb 18, 2026, 8:30 AM EST - 6 months ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 6 months ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Jan 16, 2026, 12:45 PM EST - 7 months ago

Recursion Pharmaceuticals Transcript: 28th Annual Needham Growth Conference Virtual

Jan 13, 2026, 1:30 PM EST - 7 months ago

Recursion Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Recursion Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 8 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 11:05 AM EST - 8 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Press release: Study Update

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Slides: Study Update

Dec 8, 2025, 7:32 AM EST - 9 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 9 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 1, 2025, 8:30 AM EST - 9 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 18, 2025, 5:30 AM EST - 9 months ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Slides: Q3 2025

Nov 5, 2025, 6:30 AM EST - 10 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 10 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Sep 8, 2025, 4:05 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 2:30 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 6:30 AM EDT - 1 year ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 6:14 AM EDT - 1 year ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 1 year ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 15, 2025, 10:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: 53rd Annual JPMorgan Global Technology, Media and Communications Conference

May 13, 2025, 1:00 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q1 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 12:45 PM EDT - 1 year ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 1 year ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:34 PM EDT - 1 year ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 1 year ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Annual report: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q4 2024

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: FY 2025

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 11, 2024, 10:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Bank of America Global A.I. Conference 2024

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Slides: Status Update

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Nov 20, 2024, 8:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Press release: Status Update

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 6, 2024, 7:00 AM EST - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q3 2024

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 10, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 2, 2024, 8:32 AM EDT - 2 years ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 2 years ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 4, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 3, 2024, 8:11 AM EDT - 2 years ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Invest2live Aug. 24 at 4:26 AM

$NVDA 1548% already; congrats 🪷🌟🌺 Checkout $TDC, $RXRX and $POET; excellent potential for longs. Do your DD and get in.

0 · Reply

Invest2live Aug. 24 at 4:20 AM

$UMC 138% already; congrats 🪷🌟🌺 Checkout $POET and $RXRX; both have similar or better potential. Do your DD and get in.

0 · Reply

Primitivetablemaker Aug. 23 at 5:12 PM

$RXRX In.

0 · Reply

USAEquityResearch Aug. 23 at 4:34 PM

0 · Reply

LoveRetailFroth Aug. 22 at 2:41 PM

0 · Reply

AEngelen Aug. 22 at 1:34 PM

0 · Reply

LoveRetailFroth Aug. 22 at 1:55 AM

$AMLX What week folks! $MRNA $RXRX $SANA Have a great weekend 🍺

1 · Reply

LoveRetailFroth Aug. 21 at 10:24 PM

$MRNA Hoe are the bears feeling?😂🍺 $AMLX $RXRX $SANA

0 · Reply

LoveRetailFroth Aug. 21 at 6:31 PM

$RXRX $SANA Was busy with a small psychedelic $JUNS all morning 🍺

0 · Reply

CamRanhKid Aug. 21 at 6:00 PM

$RXRX 4 coming soon

0 · Reply

apurvajobalia Aug. 21 at 5:06 PM

$RXRX Just ignore Gibson. He was the founder, and he has now been sidelined by the board. Also, a significant portion of his remuneration is in equity, so insiders selling some shares is hardly surprising. What matters is how much equity they still hold after those sales. More importantly, I would focus on the new senior people who have recently joined from highly credible positions and have accepted a substantial portion of their compensation in equity. That, to me, is a much more meaningful signal—it shows that people with strong industry knowledge are willing to put a significant part of their own compensation at risk in the company’s future.

0 · Reply

BryGuy29 Aug. 21 at 4:55 PM

$RXRX can someone shed light on why we so frequently see Form 144 sales by Gibson? Like…. Literally every day. Any thoughts ?

3 · Reply

apurvajobalia Aug. 21 at 3:32 PM

$RXRX posted in June 2026 and posting it again: Barring any market collapse, this hidden gem will catchup to its IPO price by june 2027… The next 5-10 years are golden for AI TECHBIO and RXRX 🌈🌈

0 · Reply

MakingMoney20 Aug. 21 at 3:27 PM

$RXRX On it's Journey. Buckel em... RXRX $$

0 · Reply

apurvajobalia Aug. 21 at 3:07 PM

$RXRX where is Broadman gang?! 😉😀

1 · Reply

Thelonius_Stonk Aug. 21 at 3:01 PM

$RXRX still own some. pls send

0 · Reply

ayedude Aug. 21 at 2:23 PM

$RXRX this looks like it could turn into a ferocious rebound

0 · Reply

apurvajobalia Aug. 21 at 2:15 PM

$RXRX If you’ve been following the options charts, there’s an interesting development worth watching. A significant amount of call-option open interest appears to have been closed by what many would consider “smart money.” For example, the Jan 2028 $5 call had approximately 28,000 contracts of OI two days back, which has now fallen to around 17,000 — a substantial reduction. What makes this particularly interesting is that the underlying RXRX share price has been rising at the same time. That raises an interesting question: Are some of the bears who sold those calls beginning to close their positions as the stock moves higher? Food for thought for both BEARS 🐻 and BULLS 🐂! Food for thought for both BEARS 🐻 and BULLS 🐂!

0 · Reply

LoveRetailFroth Aug. 21 at 2:02 PM

$RXRX 37% SHORT!!! Fuck them $8 🚀🚀💎 $SANA

0 · Reply

Gilthethrill Aug. 21 at 1:59 PM

$RXRX news?

0 · Reply

LoveRetailFroth Aug. 21 at 1:59 PM

$MRNA Yeah 🚀 Folks look @ $RXRX $SANA Go🚀🚀

0 · Reply

LoveRetailFroth Aug. 21 at 1:29 PM

$MRNA Good Morning my bio💎 s $AMLX $RXRX $SANA

0 · Reply

Market Cap	1.87B
Revenue (ttm)	74.68M
Net Income (ttm)	-644.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-863.36%
Debt to Equity Ratio	0.01

Volume	22,898,400
Avg Vol	20,121,941
Day's Range	N/A - N/A
Shares Out	535.34M
Stochastic %K	82%
Beta	1.03
Analysts	Sell
Price Target	$6.76